Emergent Biosolutions Inc Diversifies Its Revenue
One knock on Emergent Biosolutions (NYSE: EBS) has always been its dependence on anthrax vaccine BioThrax, but management made good on its promise to diversify, moving toward its goal of having $1 billion in revenue by 2020.
Metric
Q2 2017
Source: Fool.com
Emergent Biosolutions Inc. Stock
€4.18
-5.490%
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Emergent Biosolutions Inc..
Based on the current price of 4.18 € the target price of 12 € shows a potential of 187.22% for Emergent Biosolutions Inc. which would more than double the current price.
